Tobramycin/fosfomycin inhalation

Drug Profile

Tobramycin/fosfomycin inhalation

Alternative Names: Corus 1040; GS 9310/11; Inhaled fosfomycin/tobramycin

Latest Information Update: 24 Feb 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gilead Sciences
  • Class Aminoglycosides; Antibacterials; Epoxy compounds; Organophosphorus compounds; Phosphonic acids; Small molecules
  • Mechanism of Action Cell wall inhibitors; Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Bronchiectasis; Cystic fibrosis-associated respiratory tract infections

Most Recent Events

  • 19 Feb 2014 Tobramycin/fosfomycin inhalation licensed to CURx Pharmaceuticals worldwide
  • 08 Mar 2010 Gilead Sciences completes a phase II trial in Cystic fibrosis-associated respiratory tract infections in USA
  • 18 Oct 2007 Phase-II clinical trials in Bronchiectasis (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top